Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· April 17, 2026

Catalyst Watch: Tesla talks AI5 chips, Intel reports, and the Warner Bros. deal goes to a vote

View original at seekingalpha.com
Catalyst Watch: Tesla talks AI5 chips, Intel reports, and the Warner Bros. deal goes to a vote [Stock Exchange] ShinjiPhotographer Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Betting around the NFL draft has exploded in just the last two years for DraftKings, FanDuel, and BetMGM

    60% confidence
  • Howmet Aerospace is the stock with the tightest trading correlation to GE on earnings day

    60% confidence
  • Options trading implies a double-digit swing for ServiceNow after it reports

    60% confidence
  • Options trading implies a double-digit swing for Equifax after it reports

    60% confidence
  • Options trading implies a 9% share price move for Intel after the earnings release

    60% confidence
  • Analysts think the Adobe Summit will serve as a window into how the company is positioning its platform against broader AI adoption trends

    60% confidence
  • Options trading implies a double-digit swing for Appfolio and Mobileye Global after they report

    60% confidence
  • U.S.–Iran nuclear deal odds climb fast as July odds approach 70%

    60% confidence
  • Short interest is elevated on Lucid Group and C3.ai again

    60% confidence
  • Options trading implies a 7% share price move for GE Aerospace after the earnings release

    60% confidence
  • Options trading implies a 6% share price move for Tesla after the earnings report drops

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com